We also show that immunostaining of PODXL by our new in-house mAb gives prognostic results similar to those achieved by the commercial polyclonal antibody (HPA 2110, Atlas Antibodies, Stockholm, Sweden) in colorectal cancer [15,16]. Here, PODXL is linked to colorectal cancer.